Compare · CODX vs DXCM
CODX vs DXCM
Side-by-side comparison of Co-Diagnostics Inc. (CODX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CODX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 1588.6x CODX ($18.6M).
- Over the past year, CODX is down 43.7% and DXCM is down 10.6% - DXCM leads by 33.1 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 16 for CODX).
- DXCM has more recent analyst coverage (25 ratings vs 3 for CODX).
- Company
- Co-Diagnostics Inc.
- DexCom Inc.
- Price
- $5.05-10.62%
- $76.59+5.15%
- Market cap
- $18.6M
- $29.57B
- 1M return
- +162.95%
- +25.71%
- 1Y return
- -43.67%
- -10.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2005
- News (4w)
- 16
- 26
- Recent ratings
- 3
- 25
Co-Diagnostics Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CODX
- SEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.
- Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
- SEC Form EFFECT filed by Co-Diagnostics Inc.
- SEC Form S-3 filed by Co-Diagnostics Inc.
- Chief Executive Officer Egan Dwight H was granted 4,584 shares and returned $8,279 worth of shares to the company (1,633 units at $5.07), increasing direct ownership by 12% to 27,893 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Brown Brian Lee was granted 3,750 shares and returned $6,844 worth of shares to the company (1,350 units at $5.07), increasing direct ownership by 12% to 22,379 units (SEC Form 4) to cover taxes
- President Abbott Richard David was granted 1,890 shares and returned $3,448 worth of shares to the company (680 units at $5.07), increasing direct ownership by 55% to 3,417 units (SEC Form 4) (withholding obligation)
- Director Murphy Edward L. was granted 1,695 shares, increasing direct ownership by 18% to 11,084 units (SEC Form 4)
- Director Serbin Richard S was granted 1,695 shares, increasing direct ownership by 19% to 10,751 units (SEC Form 4)
- Director Durenard Eugene was granted 1,695 shares, increasing direct ownership by 19% to 10,668 units (SEC Form 4)
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)